Suchergebnisse - "Shou, Yaping"

PubPharm (52)

1

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659)

enthalten in: Oncotarget | 2023

von Gordon, L. | Karmali, R. | Kaplan, J. | +23

2

The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides

enthalten in: Cancer immunology, immunotherapy : CII | 2022

von Kruglov, O. | Johnson, L. | Minic, A. | +6

3

Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4+ BTLA+ T Cells in Tumor Microenvironment of Mycosis Fungoides

enthalten in: Cancers | 2021

von Jiang, T. | Kruglov, O. | Lin, G. | +6

4

Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome : a multicentre, phase 1 study

enthalten in: The Lancet. Haematology | 2021

von Querfeld, C. | Thompson, J. | Taylor, M. | +11

CommentIn: Lancet Haematol. 2021 Nov;8(11):e779-e781. - PMID 34627594

5

The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides

enthalten in: Cancer immunology immunotherapy | 2021

von Kruglov, O. | Johnson, L. | Minic, A. | +6

6

The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides

enthalten in: Cancer immunology immunotherapy | 2021

von Kruglov, O. | Johnson, L. | Minic, A. | +6

7

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Ansell, S. | Maris, M. | Lesokhin, A. | +23

8

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

enthalten in: British journal of cancer | 2020

von Voss, M. | Gordon, M. | Mita, M. | +17

9

Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors

enthalten in: Clinical pharmacology in drug development | 2020

von Patel, C. | Goel, S. | Patel, M. | +5

10

Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2020

von Gordon, L. | Kaplan, J. | Popat, R. | +21

1
2
3
4
5
6
Nächster »
[6]